Efficacy and Synergy of Small Molecule Inhibitors Targeting
FMS-like tyrosine kinase 3
WS6
acute myeloid leukemia
cabozantinib
ispinesib
ponatinib
targeted therapy
tyrosine kinase inhibitor
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
08 Dec 2021
08 Dec 2021
Historique:
received:
27
08
2021
revised:
01
12
2021
accepted:
03
12
2021
entrez:
24
12
2021
pubmed:
25
12
2021
medline:
25
12
2021
Statut:
epublish
Résumé
Constitutive activation of FLT3 by ITD mutations is one of the most common genetic aberrations in AML, present in ~1/3 of cases. Patients harboring
Identifiants
pubmed: 34944800
pii: cancers13246181
doi: 10.3390/cancers13246181
pmc: PMC8699584
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Austrian Science Fund FWF
ID : I 4157
Pays : Austria
Références
Lancet Oncol. 2017 Aug;18(8):1061-1075
pubmed: 28645776
Nat Commun. 2019 Nov 13;10(1):5140
pubmed: 31723137
Hematol Oncol Clin North Am. 2017 Aug;31(4):681-692
pubmed: 28673395
Oncogene. 2004 May 27;23(25):4454-65
pubmed: 15064750
Blood. 2002 Sep 1;100(5):1532-42
pubmed: 12176867
Clin Cancer Res. 2021 Jul 15;27(14):4003-4011
pubmed: 34103301
Lancet Oncol. 2018 Jul;19(7):889-903
pubmed: 29859851
PLoS One. 2013 Nov 13;8(11):e78556
pubmed: 24236021
Leukemia. 2019 Feb;33(2):299-312
pubmed: 30651634
Cancer Sci. 2020 Feb;111(2):312-322
pubmed: 31821677
Haematologica. 2021 Apr 01;106(4):1022-1033
pubmed: 33504139
Cancer Lett. 2016 Jul 1;376(2):218-25
pubmed: 27060207
Cells. 2020 Nov 17;9(11):
pubmed: 33212779
Cancers (Basel). 2019 Dec 03;11(12):
pubmed: 31817042
Stem Cell Investig. 2017 Jun 02;4:48
pubmed: 28607922
J Comput Chem. 2004 Oct;25(13):1605-12
pubmed: 15264254
Leukemia. 2015 Dec;29(12):2382-9
pubmed: 26172401
Blood. 2015 May 21;125(21):3236-45
pubmed: 25795921
Haematologica. 2011 Jan;96(1):62-8
pubmed: 20952518
Chem Biol Drug Des. 2011 Jan;77(1):1-11
pubmed: 21118377
Bioinformatics. 2017 Aug 1;33(15):2413-2415
pubmed: 28379339
Cancer Res. 2009 Apr 1;69(7):3032-41
pubmed: 19318574
Appl Health Econ Health Policy. 2013 Jun;11(3):275-86
pubmed: 23677706
Invest New Drugs. 2008 Jun;26(3):249-55
pubmed: 17962907
J Am Chem Soc. 2013 Feb 6;135(5):1669-72
pubmed: 23330637
Blood. 2018 Aug 9;132(6):598-607
pubmed: 29875101
Blood. 2007 Feb 15;109(4):1643-52
pubmed: 17047150
Nature. 2012 Apr 15;485(7397):260-3
pubmed: 22504184
Clin Cancer Res. 2010 Jan 15;16(2):566-76
pubmed: 20068098
Int J Mol Sci. 2019 Jul 12;20(14):
pubmed: 31336846
Blood. 2005 Jan 1;105(1):54-60
pubmed: 15345597
Nature. 1994 Apr 14;368(6472):643-8
pubmed: 8145851
Nature. 2018 Oct;562(7728):526-531
pubmed: 30333627
Curr Opin Struct Biol. 2016 Dec;41:145-150
pubmed: 27521655
Leukemia. 2021 Jul;35(7):2017-2029
pubmed: 33149267
N Engl J Med. 2015 Sep 17;373(12):1136-52
pubmed: 26376137
Nucleic Acids Res. 2019 Jul 2;47(W1):W357-W364
pubmed: 31106366
Curr Protoc Pharmacol. 2013 Mar;Chapter 2:Unit2.9
pubmed: 23456613
Recent Results Cancer Res. 2018;211:67-75
pubmed: 30069760
Haematologica. 2019 Oct;104(10):2017-2027
pubmed: 30923103
Haematologica. 2019 Oct;104(10):1907-1909
pubmed: 31575669
Leukemia. 2016 May;30(5):1025-32
pubmed: 26686245
Nucleic Acids Res. 2020 Jul 2;48(W1):W488-W493
pubmed: 32246720
Haematologica. 2017 Apr;102(4):e129-e131
pubmed: 28034991
Onco Targets Ther. 2019 Jan 18;12:635-645
pubmed: 30705592
Mol Cancer Ther. 2008 Oct;7(10):3176-86
pubmed: 18852121
Leukemia. 2018 May;32(5):1135-1146
pubmed: 29472718
Oncol Rev. 2012 Apr 17;6(1):e8
pubmed: 25992210
Crit Rev Oncol Hematol. 2019 Sep;141:125-138
pubmed: 31279288